Efficacy and safety of HER2-targeted therapy in patients with colorectal cancer: What should we expect from a meta-analysis? - 02/02/23
![](/templates/common/images/mail.png)
Highlights |
• | HER2-targeted therapy suggested promising efficacy in colorectal cancer CRC. |
• | The toxicity of HER2-targeted therapy in CRC is tolerable. |
• | Antibody-drug conjugates (ADC) might be the first choice for HER2-targeted monotherapy. |
Abstract |
Background and objective |
Human epidermal growth factor receptor 2 (HER2) is an effective therapeutic target for breast and stomach cancers. However, the application of HER2-targeted therapy in colorectal cancer (CRC) remains controversial. We sought to assess the efficacy and safety of HER2-targeted therapy in CRC by performing a meta-analysis of relevant studies.
Methods |
We searched PubMed, Embase, Cochrane Library, Web of Science, and the ClinicalTrials.gov database to retrieve relevant studies. STATA 16 was used for the statistical analysis. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and incidence of treatment‑related adverse events (TRAEs) were used as the outcome indicators analyzed by random- or fixed-effects models.
Results |
A total of 267 patients from nine studies were included in this meta-analysis. The overall ORR and DCR were 27.5% (95% CI 16.8% to 39.6%) and 68.9% (95% CI 55.4% to 81.0%), respectively. No significant heterogeneity was found in PFS among these studies and the overall median PFS was 4.35 months (95% CI 3.70 to 4.99). The overall incidence of all-grade and grade 3 or higher adverse events were 93.5% (95% CI 88.4% to 97.4%) and 16.8% (95% CI 4.8% to 33.3%).
Conclusions |
HER2-targeted therapy was confirmed as a promising treatment for colorectal cancer, warranting further high-quality clinical randomized controlled trials to verify.
El texto completo de este artículo está disponible en PDF.Keywords : HER2, HER2-targeted therapy, Colorectal cancer, Efficacy, Safety
Esquema
Menglei Wang and Jingyang Su contributed equally to the manuscript. |
Vol 47 - N° 2
Artículo 102078- février 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?